Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @uptoTate : What a great interview with @IreneBlancoMD regarding equity and inclusion in rheumatology. She is amazing! Such an important topic for all of us! #ACR20 @rheumnow https://t.co/HCnTD8XkAd
Dr. John Cush RheumNow
5 years 10 months ago
Dr. Mrinalini Dey ( @DrMiniDey) interviews Dr. James Galloway on infection in rheumatic diseases, and the studies and presentations he's interested in on infection at #ACR20.
https://t.co/5HE7ByhjXo https://t.co/77oLtO2MEQ
Dr. John Cush RheumNow
5 years 10 months ago
#BestACRO20Tweets
"RT @RHEUMarampa : Large cohort of older RA pts newly rx w/HCQ or MTX:
👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ.
@RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/4gK7hwdhIr" https://t.co/JsGBFrp7Hl
Dr. John Cush RheumNow
5 years 10 months ago
Did you know we have podcast? Search Rheum Now on Apple/Android/Soundcloud or listen directly through the link below.
https://t.co/wjBWCrKL34 https://t.co/Sin6gVXbeB
Dr. John Cush RheumNow
5 years 10 months ago
Miss anything during #ACR20? The RheumNow podcast has got it covered.
Catch our podcast on ACR20-Opening Day.
https://t.co/dG2H80Qycw https://t.co/EzNl4lm1fB
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @ejdein1 : #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/knduk3l6xV https://t.co/SNommxn1jA
Dr. John Cush RheumNow
5 years 10 months ago
SKIPPAIN Trial: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0899 presented at #ACR20.
https://t.co/yoQ8MEH2Br https://t.co/1uRKEp88le
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @ejdein1 : Worth checking out the #ACR20 image competition. Here's an image of cerebral toxoplasmosis during ADA treatment for RA https://t.co/JH07pMjvRe https://t.co/H9LHwiw4xL
Dr. John Cush RheumNow
5 years 10 months ago
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20.
https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn
Dr. John Cush RheumNow
5 years 10 months ago
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20
https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH
Dr. John Cush RheumNow
5 years 10 months ago
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20
https://t.co/zql7iySXOA https://t.co/PY9k108QTc
Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting.
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @doctorRBC : Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts.
Double-blind, Placebo, RCT (n=243)
@RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/Gi5FpodeKf https://t.co/bTk8n7dNni
Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.
